Efficacy and Safety of Rituximab Therapy for Lupus Nephritis Among SLE Female Patients; a Retrospective Hospital-Based Study

References

• Abdelgalil Ali Ahmed S, Adam Essa ME, Ahmed AF, et al. Incidence and clinical pattern of mixed connective tissue disease in Sudanese patients at Omdurman military hospital: hospital-based study. Open Access Rheumatol. 2021;13:333–341. doi:10.2147/OARRR.S335206
   PubMed Web of Science ®Google Scholar
• Ibn Idris Rodwan AA, Ahmed Elmansour OK, Ahmed AFE, et al. A rare association of thrombotic thrombocytopenic purpura with systemic lupus erythematosus in a Sudanese woman: case report. J Blood Med. 2021;12:945–949. doi:10.2147/JBM.S334689
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–730. doi:10.1038/nrrheum.2016.186
   PubMed Web of Science ®Google Scholar
• Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int. 2008;73(3):261–268. doi:10.1038/sj.ki.5002663
   PubMed Web of Science ®Google Scholar
• Bhargava R, Li H, Tsokos GC. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr Opin Rheumatol. 2022. doi:10.1097/BOR.0000000000000887
   PubMed Web of Science ®Google Scholar
• Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017;23(7):615–635. doi:10.1016/j.molmed.2017.05.006
   PubMed Web of Science ®Google Scholar
• Choi SC, Morel L. B cell contribution of the CD4(+) T cell inflammatory phenotypes in systemic lupus erythematosus. Autoimmunity. 2017;50(1):37–41. doi:10.1080/08916934.2017.1280028
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–4402. doi:10.1182/blood-2009-06-225979
   PubMed Web of Science ®Google Scholar
• Yo JH, Barbour TD, Nicholls K. Management of refractory lupus nephritis: challenges and solutions. Open Access Rheumatol. 2019;11:179–188. doi:10.2147/OARRR.S166303
   PubMed Web of Science ®Google Scholar
• Sterner RM, Hartono SP, Grande JP. The pathogenesis of lupus nephritis. J Clin Cell Immunol. 2014;5(2):115.
   Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88. doi:10.1186/1741-7015-11-88
   PubMed Web of Science ®Google Scholar
• Leone A, Sciascia S, Kamal A, Khamashta M. Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol. 2015;11(1):109–116. doi:10.1586/1744666X.2015.994508
   PubMed Web of Science ®Google Scholar
• Sinicato NA, Postal M, Appenzeller S, Niewold TB. Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy. Pharmaceut Med. 2017;31(2):81–88. doi:10.1007/s40290-017-0178-6
   PubMed Web of Science ®Google Scholar
• Postal M, Costallat LT, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol. 2012;2012:578641. doi:10.1155/2012/578641
   PubMedGoogle Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673–2677. doi:10.1002/art.10541
   PubMed Web of Science ®Google Scholar
• Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R. A critical review of clinical trials in systemic lupus erythematosus. Lupus. 2016;25(10):1122–1140. doi:10.1177/0961203316652492
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xiao L, Tang S. Annexin A2 and FTH1 are potential biomarkers for lupus nephritis. Exp Ther Med. 2018;16(5):3766–3776. doi:10.3892/etm.2018.6686
   PubMed Web of Science ®Google Scholar
• Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018;5(2):118–126. doi:10.5152/eurjrheum.2018.17096
   PubMed Web of Science ®Google Scholar
• Machado RIL, Scheinberg MA, Queiroz MY, et al. Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review. Einstein. 2014;12:36–41. doi:10.1590/S1679-45082014AO2706
   PubMedGoogle Scholar
• Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56(4):1263–1272. doi:10.1002/art.22505
   PubMed Web of Science ®Google Scholar
• Melander C, Sallee M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. CJASN. 2009;4(3):579–587. doi:10.2215/CJN.04030808
   PubMed Web of Science ®Google Scholar
• Abadie K, Hege KM. Severe refractory autoimmune hemolytic anemia with five-year complete hematologic response to third course of treatment with rituximab: a case report. J Med Case Rep. 2014;8:175. doi:10.1186/1752-1947-8-175
   PubMedGoogle Scholar
• Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614–619. doi:10.1056/NEJM198603063141004
   PubMed Web of Science ®Google Scholar
• Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupus nephritis management renaissance. Kidney Int. 2022;101(2):242–255. doi:10.1016/j.kint.2021.09.012
   PubMed Web of Science ®Google Scholar
• Tamirou F, Houssiau FA. Management of lupus nephritis. J Clin Med. 2021;10(4):670. doi:10.3390/jcm10040670
   PubMed Web of Science ®Google Scholar
• Roccatello D, Sciascia S, Rossi D, et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant. 2011;26(12):3987–3992. doi:10.1093/ndt/gfr109
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–233. doi:10.1002/art.27233
   PubMed Web of Science ®Google Scholar
• Zhong Z, Li H, Zhong H, Zhou T. Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther. 2019;13:845–856. doi:10.2147/DDDT.S195113
   PubMed Web of Science ®Google Scholar
• Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev. 2009;8(4):343–348. doi:10.1016/j.autrev.2008.11.006
   PubMed Web of Science ®Google Scholar